Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three versus six cycles of platinum-based chemotherapy before maintenance avelumab in advanced bladder cancer
ISRCTN15750433Phase 2Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of avelumab, gemcitabine, cisplatin and carboplatin in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Quality of life. Started Dec 2021; status: active, not recruiting.
02
Drugs
avelumabgemcitabinecisplatincarboplatin
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on ISRCTN15750433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15750433.